Literature DB >> 24033587

Predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients.

C Deng1, T Liu, K Wu, S Wang, L Li, H Lu, T Zhou, D Cheng, X Zhong, W Lu.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: There are numerous studies on population pharmacokinetics of vancomycin in adult patients. However, there is no such research for Chinese adult patients. This study was conducted to evaluate the predictive performance of reported population pharmacokinetic models of vancomycin in Chinese adult patients and to identify some models appropriate for our population.
METHODS: A literature search was conducted in PubMed to obtain the population pharmacokinetic models of vancomycin published between December 2010 and September 2012. The models were assessed using concentration data collected from Chinese patients for external validation. Models with relatively poor predictability were excluded from further analysis. The performance of the remaining models was evaluated in patients with different levels of creatinine clearance, age, body weight and sex by Bayesian method. This method was also used to compare the predictive performance based on peak concentration and trough concentration and the predictability based on different number of observed concentrations.
RESULTS: One hundred and sixty-five blood concentrations from 72 Chinese adult patients were collected retrospectively to serve as the test data set. The evaluated models included all those reported in the seven publications reviewed by Marsot et al. and three other studies published after December 2010. Three models with poor performance on external validation were excluded from the next Bayesian analysis. The distribution of covariates in the model building data set had an important effect on prediction. The predictability based on peak/trough concentration was similar among the evaluated models, and no significant difference was found using our data set except for Roberts' model. As expected, an increased number of samples improved the performance of the Bayesian prediction. WHAT IS NEW AND
CONCLUSION: With our data set, the performance of the evaluated models varied. The characteristics of the patient population and distribution of covariates should be given more consideration when choosing a model to predict blood concentrations. The model developed by Purwonugroho et al. using a data set from patients similar to ours is appropriate for Bayesian dose predictions for vancomycin concentrations in our population of Chinese adult patients.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Bayesian method; NONMEM; external evaluation; population pharmacokinetics; target concentration intervention; vancomycin

Mesh:

Substances:

Year:  2013        PMID: 24033587     DOI: 10.1111/jcpt.12092

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  11 in total

1.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

2.  Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria.

Authors:  Yuma A Bijleveld; Maria E van den Heuvel; Caspar J Hodiamont; Ron A A Mathôt; Timo R de Haan
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

4.  External Evaluation of Population Pharmacokinetic Models of Vancomycin in Large Cohorts of Intensive Care Unit Patients.

Authors:  Tingjie Guo; Reinier M van Hest; Luca F Roggeveen; Lucas M Fleuren; Patrick J Thoral; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

5.  Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.

Authors:  Can Hu; Wen-Jun Yin; Dai-Yang Li; Jun-Jie Ding; Ling-Yun Zhou; Jiang-Lin Wang; Rong-Rong Ma; Kun Liu; Ge Zhou; Xiao-Cong Zuo
Journal:  Eur J Clin Pharmacol       Date:  2018-07-17       Impact factor: 2.953

6.  Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function.

Authors:  Siriluk Jaisue; Cholatip Pongsakul; David Z D'Argenio; Pakawadee Sermsappasuk
Journal:  Ther Drug Monit       Date:  2020-12       Impact factor: 3.118

7.  Establishment of a population pharmacokinetics model of vancomycin in 94 infants with septicemia and its application in individualized therapy.

Authors:  Zhiling Li; Hongjing Li; Chenyu Wang; Zheng Jiao; Feng Xu; Huajun Sun
Journal:  BMC Pharmacol Toxicol       Date:  2021-05-04       Impact factor: 2.483

8.  Population Pharmacokinetics of Vancomycin in Chinese ICU Neonates: Initial Dosage Recommendations.

Authors:  Zhi-Ling Li; Yi-Xi Liu; Zheng Jiao; Gang Qiu; Jian-Quan Huang; Yu-Bo Xiao; Shu-Jin Wu; Chen-Yu Wang; Wen-Juan Hu; Hua-Jun Sun
Journal:  Front Pharmacol       Date:  2018-06-26       Impact factor: 5.810

9.  Optimizing Predictive Performance of Bayesian Forecasting for Vancomycin Concentration in Intensive Care Patients.

Authors:  Tingjie Guo; Reinier M van Hest; Laura B Zwep; Luca F Roggeveen; Lucas M Fleuren; Rob J Bosman; Peter H J van der Voort; Armand R J Girbes; Ron A A Mathot; Paul W G Elbers; Johan G C van Hasselt
Journal:  Pharm Res       Date:  2020-08-23       Impact factor: 4.200

10.  Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia.

Authors:  Xuan Gao; Xiao-Wen Qian; Xiao-Hua Zhu; Yi Yu; Hui Miao; Jian-Hua Meng; Jun-Ye Jiang; Hong-Sheng Wang; Xiao-Wen Zhai
Journal:  Front Pharmacol       Date:  2021-07-13       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.